What is the recommended uptitration schedule for Qsymia (phentermine/topiramate) for weight loss?

Qsymia Uptitration Schedule

Start Qsymia at 3.75 mg/23 mg once daily for 14 days, then increase to 7.5 mg/46 mg daily; if inadequate weight loss after 12 weeks, escalate to 11.25 mg/69 mg for 14 days followed by 15 mg/92 mg daily. 1

Initial Dosing Phase

• Begin with 3.75 mg phentermine/23 mg topiramate once daily in the morning for 14 days 1
• Take with or without food 1
• Avoid evening administration due to insomnia risk 1

Standard Maintenance Dose

• After the initial 14 days, increase to 7.5 mg/46 mg once daily 2, 1
• This represents the standard maintenance dose for most patients 2
• Continue this dose and reassess at 12 weeks 1

Dose Escalation Decision Point (12 Weeks)

Evaluate weight loss at 12 weeks on 7.5 mg/46 mg: 1

• If <3% body weight loss in adults OR <3% BMI reduction in adolescents: Escalate dose 1
• If ≥3% weight loss achieved: Continue current dose 1

Maximum Dose Titration

For patients requiring dose escalation: 1

• Increase to 11.25 mg/69 mg once daily for 14 days 2, 1
• Then advance to 15 mg/92 mg once daily (maximum dose) 2, 1
• Reassess after 12 weeks on maximum dose 1

Second Evaluation Point (12 Weeks on Maximum Dose)

At 12 weeks on 15 mg/92 mg: 1

• If <5% body weight loss in adults OR <5% BMI reduction in adolescents: Discontinue medication 1
• Discontinuation requires gradual taper: take 15 mg/92 mg every other day for at least 1 week before stopping completely to prevent seizure risk 1

Special Populations Requiring Dose Modification

Moderate or severe renal impairment (CrCl 30-50 mL/min or <30 mL/min): 1

• Maximum dose is 7.5 mg/46 mg once daily 1
• Avoid in end-stage renal disease on dialysis 1

Moderate hepatic impairment (Child-Pugh 7-9): 1

• Maximum dose is 7.5 mg/46 mg once daily 1
• Avoid in severe hepatic impairment (Child-Pugh 10-15) 1

Clinical Pearls

The 2022 AGA guidelines recommend targeting the 15 mg/92 mg dose when tolerated, as this demonstrated superior efficacy compared to the 7.5 mg/46 mg dose, with weight loss of 9.8% versus 7.8% respectively 2. The higher dose should be pursued as long as the benefit-risk balance remains favorable for the individual patient 2.

Common pitfalls to avoid: 2

• Failing to titrate gradually increases side effect burden (paresthesias, dizziness, dysgeusia) 2
• Not reassessing at the 12-week intervals leads to continued use in non-responders 1
• Abrupt discontinuation of the maximum dose risks precipitating seizures due to the topiramate component 1

In pediatric patients, monitor weight loss rate and consider dose reduction if exceeding 2 lbs (0.9 kg) per week 1.